Clinically-Occult Mixed Cellularity Hodgkin's Disease with Charcot-Leyden Crystals

References

• Leyden E. Zur Kenntnis des Bronchialasthma. Arch. Pathol. Anal. 1872; 54: 324–352
   Google Scholar
• Sakula A. Charcot-Leyden crystals and Curschmann's spirals in asthmatic sputum. Thorax 1986; 41: 503–507
   PubMed Web of Science ®Google Scholar
• Junod C. Isospora belli coccidiosis in immunocompetent subjects (a study of 40 cases seen in Paris). Bull, de la Soc. de Pathol. Exot. et de Ses. Filial. 1988; 81: 317–325
   PubMed Web of Science ®Google Scholar
• Naylor B., Novak D. M. Charcot-Leyden crystals inpleural fluids. Acta Cytol 1985; 29: 781–784
   PubMed Web of Science ®Google Scholar
• Del Blanco J., Valverde J., Mateo L., Juanola X., Pons M., Ferrer J. Charcot-Leyden crystals in synovial fluid. J. Rheum. 1991; 18: 1944
   PubMed Web of Science ®Google Scholar
• Charcot J. M., Robin C. Observations de leucocythemie. C. R. Mem. Soc. Biol. (Paris) 1853; 5: 44–50
   Google Scholar
• Kanner R. E., Hammar S. P. Chronic eosinophilic pneumonia: Ultrastructural evidence of marked immunoglobulin production plus macrophagic ingestion of eosinophils and eosinophilic lysosomes leading to intracytoplasmic Charcot-Leyden crystals. Chest 1977; 71: 95–98
   PubMed Web of Science ®Google Scholar
• Schnitzler L., Verret J. L., Schubert B. Granuloma faciale: Ultrastructural study of three cases. J. Cutan. Pathol. 1977; 4: 123–133
   PubMed Web of Science ®Google Scholar
• Chalifoux L. V., King N. W. Eosinophilic myelocytomain an owl monkey (Aotus trivirgatus). Lab. Anim. Sci. 1983; 33: 189–191
   PubMedGoogle Scholar
• Kuto F., Nagaoka T., Watanabe Y., et al. Chronic myelocytic leukemia: ultrastructural histopathology of bone marrow from patients in the chronic phase. Ultrastruct. Pathol. 1984; 6: 307–317
   PubMed Web of Science ®Google Scholar
• Kanitakis J., Schmitt D., Euvrard S., Thivolet J. Ultrastructural observation of Charcot-Leyden crystals in mechlorethamine-treated cutaneous lesions of histiocytosis X. J. Am. Acad. Dermatol. 1986; 3: 483–486
   Web of Science ®Google Scholar
• Carson H. J., Buschmann R. J., Weisz-Carrington P., Choi Y. S. Identification of Charcot-Leyden crystals by electron microscopy. Ultrastruct. Pathol. 1992; 16: 403–411
   PubMed Web of Science ®Google Scholar
• Dvorak A. M., Letourneau L., Weller P. F., Ackerman S. J. Ultrastructural localization of Charcot-Leyden crystal protein (lysophospholipase) to intracytoplasmic crystals in tumor cells of primary solid and papillary epithelial neoplasm of the pancreas. Lab. Invest. 1990; 62: 590–607
   PubMed Web of Science ®Google Scholar
• Weller P. F., Goetzl E. J., Austen K. F. Identification of human eosinophil lysophospholipase as the constituent of Charcot-Leyden crystals. Proc. Natl. Acad. Sci. USA 1980; 77: 7440–7443
   PubMed Web of Science ®Google Scholar
• Gleich G. J., Loegering D. A., Mann K. G., Maldonado J. E. Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J. Clin. Invest. 1976; 57: 633–40
   PubMed Web of Science ®Google Scholar
• Ackerman S. J., Durack D. T., Gleich G. J. Eosinophil effector mechanisms in health and disease. Advances in Host Defense Mechanisms, J. I. Gallin, A. S. Fauci. Raven, New York 1982; 265–293
   Google Scholar
• Jong E. C., Klebanoff S. J. Eosinophil-mediated mammalian tumor cell cytotoxicity: role of the peroxidase system. J. Immunol. 1980; 124: 1949–1953
   PubMed Web of Science ®Google Scholar
• Reinbach G. Uber des Verhalten der Leukozyten bei malignen Tumoren. Arch. Klin. Chir. 1893; 46: 486–562
   Google Scholar
• Isaacson N. H., Rapoport P. Eosinophilia in malignant tumors: Its significance. Ann. Intern. Med. 1946; 25: 893–902
   PubMed Web of Science ®Google Scholar
• Bostrom S. G., Hart W. R. Carcinoma of the cervix with intense stromal eosinophilia. Cancer 1981; 47: 2887–2893
   PubMed Web of Science ®Google Scholar
• Butterfield J. H., Dephart G. M., Banks P. M., Gleich G. J. Extracellular deposition of eosinophil granule major basic protein in lymph nodes of patients with Hodgkin's disease. Blood 1986; 68: 1250–1256
   PubMed Web of Science ®Google Scholar
• Ghadially F. N., Murphy F., Lalond J.-M. A. Eosinophil-mediated necrosis in a malignant fibrous histiocytoma. Ann. Pathol.(Paris) 1982; 2: 57–9
   Google Scholar
• Lukes R. J., Craver L. F., Hall T. C., Rappaport H., Ruben P. Report of the Nomenclature Committee. Cancer Res. 1966; 26: 1311
   Web of Science ®Google Scholar
• Anastasi J., Bitter M. A., Vardiman J. W. The histopathologic diagnosis and subclassification of Hodgkin's disease. Hem. Oncol. Clin. North Am. 1989; 3: 187–204
   PubMed Web of Science ®Google Scholar
• Hodgkin's disease. American Joint Committee on Cancer Manual for Staging of CancerFourth Edition, O. H. Beahrs, D. E. Henson, R. V. P. Hutter, B. J. Kennedy. J. B. Lippincott, Philadelphia 1992; 253–255
   Google Scholar
• Ben-Ezra J., Sheibani K., Swartz W., Stroup R., Traveele S. T., Kezirian J., Rappaport H. Relationship between eosinophil density and T-cell activation markers in lymph nodes of patients with Hodgkin's disease. Hum. Pathol. 1989; 20: 1181–5
   PubMed Web of Science ®Google Scholar
• Samoszuk M., Sholly S., Epstien A. L. Eosinophil peroxidase is detectable with a monoclonal antibody in collagen bands of nodular sclerosis Hodgkin's disease. Lab. Invest. 1987; 56: 394–400
   PubMed Web of Science ®Google Scholar
• Samoszuk M. K., Nathwani B. N., Lukes R. J. Extensive deposition of eosinophil peroxidase in Hodgkin's and non-Hodgkin's lymphomas. Am. J. Pathol. 1986; 125: 426–429
   PubMed Web of Science ®Google Scholar
• Kadin M., Butmarc J., Elovic A., Wong D. Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease. Am. J. Pathol. 1993; 142: 11–16
   PubMed Web of Science ®Google Scholar
• Strum S. B., Rappaport H. The persistence of Hodgkin's disease in long-term survivors. Am. J. Med. 1971; 51: 222–40
   PubMed Web of Science ®Google Scholar